Curaleaf (CURA) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
6 Nov, 2025Executive summary
Third quarter revenue reached $320 million, up 2% sequentially but down 3% year-over-year, reflecting stabilization in domestic operations and robust international growth despite ongoing price compression headwinds.
The "Return to Our Roots" plan has driven improvements in product quality, supply chain, and retail operations, positioning the business for renewed growth domestically and rapid international expansion.
International segment delivered 12% sequential and 56% year-over-year revenue growth, with strong performance in the U.K. and Germany, and new product launches like the QMID device and ACE oil driving engagement.
Adjusted gross profit margin improved to 50%, up 115 basis points both sequentially and year-over-year.
Adjusted EBITDA for Q3 was $69.3 million (21.6% margin), with $107.5 million in cash at quarter end after $28 million in debt payments.
Financial highlights
Adjusted gross margin improved to 50%, up 115 basis points both sequentially and year-over-year, driven by cost reductions in cultivation.
Adjusted EBITDA was $69.3 million (21.6% margin), down 8% year-over-year, with international and hemp businesses dragging margins by 200 basis points.
Net loss from continuing operations was $54.5 million ($0.07 per share); adjusted net loss was $48.2 million ($0.06 per share).
Operating cash flow from continuing operations was $53 million for the quarter and $104 million year-to-date; free cash flow was $37 million in Q3 and $56.8 million year-to-date.
Ended the quarter with $107.5 million in cash and $543.7 million in outstanding debt.
Outlook and guidance
Fourth quarter revenue expected to increase low single digits sequentially.
Anticipates shifting to a growth mindset in 2026 as foundational restructuring is largely complete.
No meaningful revenue expected from new international markets (Turkey, Spain, France) until 2027 and beyond.
Cautiously optimistic about strengthening domestic business and confident in multiple growth drivers for 2026.
Continued international expansion and domestic retail optimization are expected to drive future growth.
Latest events from Curaleaf
- Q4 revenue hit $333M, margins improved, and international growth accelerated despite pricing pressure.CURA
Q4 202526 Feb 2026 - Board size set at 10, all directors and auditor approved, with no questions from shareholders.CURA
AGM 20243 Feb 2026 - Q2 revenue up 2% to $342M, with 78% international growth and 48% adjusted gross margin.CURA
Q2 20242 Feb 2026 - Q3 saw stable revenue, margin gains, and 82% international growth amid U.S. market pressures.CURA
Q3 202416 Jan 2026 - Six directors elected, board set at 10, and auditor appointed with no shareholder questions.CURA
AGM 202513 Jan 2026 - 2024 revenue flat at $1.34B; international sales up 73% and margins improved.CURA
Q4 202423 Dec 2025 - International growth and product launches offset U.S. price pressure, driving Q2 results.CURA
Q2 202523 Nov 2025 - Q1 revenue fell 6% to $310M, but gross margin rose to 50% amid strong international growth.CURA
Q1 202517 Nov 2025